Belimumab
Looking for the plain-language version? See the patient version of this page.
Dosing and administration[2]
For active autoantibody-positive SLE (and lupus nephritis). Available intravenously and subcutaneously.
| Indication | Starting dose | Titration and maximum |
|---|---|---|
| Systemic lupus erythematosus (IV) | 10 mg/kg IV at weeks 0, 2, and 4, then every 4 weeks. | Continue as maintenance; reassess response. |
| Systemic lupus erythematosus (subcutaneous) | 200 mg subcutaneously once weekly. | Maintenance weekly dosing. |
Monitoring
- Monitor for infusion or injection reactions and infection.
- Assess for new or worsening depression and suicidality (reported in trials).
Contraindications
- Hypersensitivity to belimumab.
- Caution with severe active central nervous system lupus.
Key interactions
- Avoid live vaccines within 30 days before or during treatment.
- Combination with cyclophosphamide or other biologics has not been well studied.
Clinical notes
How it is used in lupus
An add-on biologic for SLE to reduce activity and flares, and one of the combination-therapy options in lupus nephritis.[1]
Common side effects
Infusion or injection-site reactions and increased infection risk occur; mood changes, including depression, have been reported. Described from background clinical knowledge and the Table 5 monitoring note; reconcile with the product monograph.
Tests and monitoring
Monitor for new or worsening depression or suicidal thoughts.[1]
Before you start
Screen for hepatitis B, tuberculosis, and HIV before starting, as for other immunosuppressive and biologic therapy, and address vaccination beforehand.[1]
Important cautions
Reproductive-safety data are more limited; individualise, with full guidance maintained on the pregnancy record. Avoid live vaccines during treatment.
References
- Sammaritano LR, Askanase A, Bermas BL, et al. 2025 American College of Rheumatology (ACR) Guideline for the Treatment of Systemic Lupus Erythematosus. Arthritis Care Res (Hoboken). 2025. doi:10.1002/acr.25690 https://doi.org/10.1002/acr.25690
- BENLYSTA (belimumab) Product Monograph. Health Canada authorized product monograph. https://health-products.canada.ca/dpd-bdpp/